Absci (ABSI) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 20, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Absci EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Absci's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Absci's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Absci's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Absci's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Absci's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Absci (NAS:ABSI) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Absci EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Absci's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Absci (ABSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683

Website

https://www.absci.com

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Executives

Frans Van Houten	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj	director	400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman	officer: General Counsel	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick	officer: VP, CCPAO	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh	director	C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain	director, 10 percent owner, officer: President and Chief Executive	18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis	director	INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p.	director, 10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc	10 percent owner	1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel	officer: Chief Business Officer	101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660